The use of B-cell targeted therapies for the treatment of systemic lupus erythematosus (SLE) has generated great interest owing to the multiple pathogenic roles carried out by B cells in this disease.

It is my view that B-cell therapy will likely become an important part of the treatment paradigm in SLE over the next 3–5 years. I think the data are suitably strong to justify the approval of ...